Biobank Japan Project

Biobank Japan Project
Name	Biobank Japan Project
Established	2003
Location	Tokyo, Osaka, Sapporo
Type	Medical biobank, cohort study
Director	Masahiro Kubo

Biobank Japan Project is a large-scale genomic and clinical biobank established to accelerate translational research and precision medicine in Japan. It links genotype and phenotype data with longitudinal clinical outcomes to study common diseases and pharmacogenomics across Japanese populations. The Project operates through major institutions, hospitals, and research centers to enable population-based and disease-specific investigations.

Overview

The initiative was launched to integrate data from hospitals such as The University of Tokyo Hospital, Osaka University Hospital, Hokkaido University Hospital, Keio University Hospital, Kyoto University Hospital, and Nagoya University Hospital with genomic analyses performed at institutions including RIKEN, National Center for Global Health and Medicine, Tohoku University, University of Tsukuba, Osaka University, and Kyoto University to support studies in diseases like type 2 diabetes mellitus, coronary artery disease, stroke, asthma, and rheumatoid arthritis. Steering and advisory roles have involved organizations such as the Ministry of Health, Labour and Welfare (Japan), Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Tokyo Medical and Dental University, and National Center for Geriatrics and Gerontology. The biobank connects clinical cohorts with resources including genotype arrays developed by Illumina, sequencing platforms from Thermo Fisher Scientific, and analytical collaborations with groups at Broad Institute, Wellcome Sanger Institute, and University of Oxford.

History and Development

The Project began in 2003 as a national effort supported by policymakers in Tokyo, with early conferences held alongside meetings at Yokohama Bay Hall and collaborative symposia involving investigators from Kyushu University, Okinawa Institute of Science and Technology Graduate University, Fujita Health University, Kindai University, and Tohoku Medical Megabank Organization. Initial funding rounds included awards from Japan Science and Technology Agency and grants linked to national health strategies debated at the Diet of Japan. Key early publications featured coauthors from University of California, San Francisco, University of Cambridge, Harvard Medical School, and Peking University reflecting rapid international engagement. Over successive phases the infrastructure expanded through partnerships with hospitals such as Saitama Medical University Hospital, Saga University Hospital, and Kobe University Hospital and technology transfers involving Illumina, PacBio, and Oxford Nanopore Technologies.

Cohort and Participant Recruitment

Participant recruitment targeted patients receiving care at partner hospitals including St. Luke's International Hospital, Juntendo University Hospital, Showa University Hospital, Kagoshima University Hospital, and Chiba University Hospital, aiming to enroll individuals with diagnoses such as diabetes mellitus, hypertension, hyperlipidemia, chronic obstructive pulmonary disease, and hepatitis C. Recruitment protocols were coordinated with institutional review boards at Gunma University Hospital, Shiga University of Medical Science, Toho University Omori Medical Center, Kurume University Hospital, and Niigata University Medical and Dental Hospital. Cohort characteristics have been described in papers with collaborators from Stanford University School of Medicine, Johns Hopkins University School of Medicine, Seoul National University Hospital, and Monash University.

Data Collection and Biospecimens

Biospecimens include DNA, serum, plasma, and archived pathology specimens collected at sites such as National Cancer Center Hospital, Cancer Institute Hospital of JFCR, Kawasaki Medical School Hospital, and Iwate Medical University Hospital. Genotyping and sequencing efforts utilized resources from Genome Institute of Singapore, McGill University Health Centre, Karolinska Institutet, Erasmus MC, and University of Copenhagen. Clinical data elements were harmonized with electronic health records from Sapporo City General Hospital and imaging repositories from Osaka City University Hospital and linked to outcome registries like those maintained by Japanese Circulation Society and Japan Stroke Society. Biochemical assays were standardized using protocols aligned with Clinical and Laboratory Standards Institute guidance and quality oversight from Japan Medical Association partners.

Research Findings and Contributions

Analyses from the Project have contributed to discoveries in loci associated with type 2 diabetes mellitus, gout, osteoporosis, atopic dermatitis, coronary artery disease, and age-related macular degeneration with publications coauthored with teams at Broad Institute, Wellcome Sanger Institute, University of Michigan, Imperial College London, ETH Zurich, and Max Planck Society. Pharmacogenomic findings informed relationships between variants and responses to medications such as statins studied with collaborators at AstraZeneca, Takeda Pharmaceutical Company, Daiichi Sankyo, and Eli Lilly and Company. The Project has contributed data to meta-analyses involving consortia like the Global Lipids Genetics Consortium, CARDIoGRAMplusC4D, GIANT Consortium, and International Stroke Genetics Consortium enhancing trans-ethnic genetic architecture studies alongside datasets from UK Biobank, All of Us Research Program, China Kadoorie Biobank, and Icelandic deCODE genetics.

Governance, Ethics, and Data Access

Governance frameworks were established with guidance from bioethics bodies including The Nuffield Council on Bioethics, The Hastings Center, Japanese Association of Bioethics, Ethics Committee of RIKEN, and institutional review boards at partnering hospitals. Consent models and data access policies aligned with international norms advocated by groups such as Global Alliance for Genomics and Health, OECD, World Health Organization, and United Nations Educational, Scientific and Cultural Organization to manage privacy, data sharing, and secondary use. Data access committees include representatives from National Center for Global Health and Medicine, RIKEN Center for Integrative Medical Sciences, Japan Agency for Medical Research and Development, and legal advisors experienced with frameworks like Act on the Protection of Personal Information (Japan).

Collaborations and Impact on Precision Medicine

International collaborations involve institutions such as Harvard T.H. Chan School of Public Health, Yale School of Medicine, University of Toronto, University of Sydney, Seoul National University, Peking University Health Science Center, and industry partners including Illumina, Thermo Fisher Scientific, Roche, and GlaxoSmithKline. The Project’s datasets have informed predictive models used in clinical settings at The University of Tokyo Hospital and risk stratification tools validated in cohorts from Seoul National University Hospital and Mayo Clinic. Contributions have advanced pharmacogenomic implementation relevant to regulators like Pharmaceuticals and Medical Devices Agency (Japan) and health policy discussions at the Ministry of Health, Labour and Welfare (Japan), promoting personalized approaches in cardiovascular medicine, oncology, and metabolic disease management.

Category:Biobanks Category:Medical research in Japan Category:Genomic projects